Brief: Cocrystal Pharma Inc Affirms Plans To Report Topline Phase 1 Results In 2022 Andto Initiatephase 2A Influenza Human Challenge Trial In 2023
01/12/2022 21:21
Dec 1 (Reuters) - Cocrystal Pharma Inc COCP.O :
* AFFIRMS PLANS TO REPORT TOPLINE PHASE 1 RESULTS IN 2022
ANDTO
INITIATEPHASE 2A INFLUENZA HUMAN CHALLENGE TRIAL IN 2023
Source text for Eikon: ID:nGNXdZMSK
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway